Tests a nutrition app and food vouchers for heart failure patients
Tests a nutrition app and food vouchers in adults with heart failure.
Plain-language title generated from the registry record
Registry title: Heart Failure Food Intervention Trial: Impact of a Guideline-based Nutrition Digital Tool in Heart Failure Patient Clinical Outcomes
Key facts
- Where
- Walnut Creek, United StatesSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 89 years old?
Source: NCT06999369, who can take part
Where in United States
- 2121 N. California Blvd., Suite 310Walnut Creek, United StatesNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Sutter Health
- Trial code
- NCT06999369
- Record updated
- 31 May 2025
- Original description
Measuring the impact of a guideline-based nutrition digital tool in heart failure patientsRead full original descriptionShow less
Heart Failure Food Intervention Trial (HF-FIT): Impact of a Guideline-based Nutrition Digital Tool in Heart Failure Patient Clinical Outcomes
Measuring the impact of a guideline-based nutrition digital tool in heart failure patients
Inclusion: 18-89 years old at time of enrollment; Any type of Heart failure diagnosis (e.g., I50.x) between 1/1/2023-present; Recent hospital admission (within a year); Race/ethnicity: All race/ethnic groups; Location: patients have been treated in the Greater East Bay division and Greater Silicon Valley division areas; Patients with have at least 1 office/outpatient visit with a primary care physician or cardiologist visit before index date.
Exclusion: • Patients with certain patient history (cognitive disabilities) and end stage renal or metastatic cancer diagnosis; Patients with active drug/substance use. Patients with heart failure who have active substance use are excluded from the study. HF patients with substance use require additional monitoring and follow up due to potential severe withdrawal symptoms, acute HF exacerbation and drug overdose or medication errors. Standard protocol includes additional monitor vital signs (e.g., blood pressure, heart rate) and HF symptoms (e.g., edema, dyspnea), and performing regular laboratory tests (e.g., renal function, electrolytes) which is beyond the clinical and logistical capabilities of this study.